ITGB2
ENSG00000160255
Target class
Membrane receptor
Chromosome
21
Approved drugs
2
Clinical candidates (approved and in development)
6
- Approved drugs
- 2
- Clinical candidates (approved and in development)
- 6
- Chemical probe available
- No
- Target name
- ITGB2
- Gene name
- Integrin subunit beta 2
- Gene symbol
- ITGB2
- Protein name
- Integrin beta-2 (Cell surface adhesion glycoproteins LFA-1/CR3/p150,95 subunit beta) (Complement receptor C3 subunit beta) (CD antigen CD18)
- LFA-1
- MAC-1
- CD18
- MFI7
- Gene biotype
- Protein coding
- Gene family
- CD molecules|Integrin beta subunits|Complement system regulators and receptors
- Target class
- Membrane receptor
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 532.59
- Tissue specificity (Gini)
- 0.734
- Tissue specificity (tau)
- 0.967
- KEGG gene identifiers
- hsa:3689
- Protein interaction confidence
- 0.863992
- Protein interaction partners
- 133
- R-HSA-166016
- R-HSA-198933
- R-HSA-202733
- R-HSA-216083
- R-HSA-6785807
- R-HSA-6798695
- End position
- 44932079
- Start position
- 44885948
- Chromosome
- 21
- Strand
- Reverse
- Cell membrane
- Single-pass type I membrane protein . Membrane raft
- Single-pass type I membrane protein .
- Plasma membrane
- Rods & Rings
- PubMed 16301335
- PubMed 21193407
- PubMed 28807980
- Tissue specificity (tau)
- 0.966633
- Expression inequality (Gini)
- 0.734139
Expression in transcripts per million
- Whole Blood
- 532.59
- Spleen
- 189.62
- Cells - EBV-transformed lymphocytes
- 124.63
- Lung
- 97.54
- Adipose - Subcutaneous
- 38
Expression in transcripts per million
- Whole Blood532.59
- Spleen189.62
- Cells - EBV-transformed lymphocytes124.63
- Lung97.54
- Adipose - Subcutaneous38
- Adipose - Visceral (Omentum)36.22
- Artery - Coronary31.62
- Small Intestine - Terminal Ileum31.5
- Artery - Aorta30.93
- Nerve - Tibial22.41
- Brain - Spinal cord (cervical c-1)20
- Cervix - Endocervix19.2
- Adrenal Gland17.92
- Bladder16.96
- Fallopian Tube16.73
- Breast - Mammary Tissue15.77
- Minor Salivary Gland15.64
- Colon - Transverse13.34
- Artery - Tibial12.41
- Colon - Sigmoid11.48
- Esophagus - Muscularis9.84
- Thyroid9.77
- Prostate9.52
- Esophagus - Gastroesophageal Junction9.24
- Uterus9.11
And 29 more, listed on the interactive page.
- GO:0006909
- GO:0007155
- GO:0007158
- GO:0007159
- GO:0007160
- GO:0007229
- GO:0030593
- GO:0032930
- GO:0033627
- GO:0033631
- GO:0034113
- GO:0035987
- GO:0043113
- GO:0043315
- GO:0050730
- GO:0061756
- GO:1990266
- GO:0005886
- GO:0008305
- GO:0009986
- GO:0016020
- GO:0034687
- GO:0034688
- GO:0034689
- GO:0034690
- GO:0035579
- GO:0043235
- GO:0044853
- GO:0045121
- GO:0070062
- GO:0070821
- GO:0101003
- GO:1903561
- GO:0004895
- GO:0005178
- GO:0005515
- GO:0019901
- GO:0030369
- GO:0031072
- GO:0050839
Related records
Trials (74)
- A Multicentre, Open Label Phase IIIb/IV Study of Subcutaneously Administered Raptiva in the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis
- A Phase 3 Study to Evaluate the Efficacy of Lifitegrast in Subjects With Dry Eye
- A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects With Dry Eye Disease
- A Safety and Efficacy Study to Evaluate Efalizumab in Combination With UVB for Moderate to Severe Psoriasis
- A Study Evaluating the Efficacy of SAR 1118 (0.1%, 1.0%, 5.0%) Ophthalmic Solution in Subjects With Dry Eye Conducted in a Controlled Adverse Environment (CAE)
- A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease
- A Study of Efalizumab in Participants With Moderate to Severe Chronic Psoriasis Who Have Failed, Have a Contraindication to, or Are Intolerant of Other Systemic Therapies
- A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Disease
- A Study to Assess the Long-Term Safety of Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination in Subjects With Dry Eye Disease
- A Study to Evaluate Efalizumab Compared With Cyclosporine As an Immunosuppressant Regimen in De Novo Renal Transplantation
- A Study to Evaluate Efalizumab in Adults With Plaque Psoriasis, Including Those Who Are Receiving Concomitant Antipsoriatic Therapies
- A Study to Evaluate Efficacy and Safety of Lifitegrast in Subjects With Dry Eye (OPUS-3)
- A Study to Evaluate Raptiva in Adults With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
- A Study to Evaluate Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2390g
- A Study to Evaluate Raptiva in Combination With Topical Psoriasis Therapies
- A Study to Evaluate Raptiva in Subjects With Chronic Moderate or Worse Plaque Psoriasis Who Have Had an Inadequate Response to an Anti-TNF Agent
- A Study to Evaluate the Effects of Efalizumab on Immune Responses in Subjects With Moderate Plaque Psoriasis
- A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Moderate to Severe Plaque Psoriasis With Involvement of the Scalp
- A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Plaque Psoriasis Involving the Hands and/or Feet
- A Study to Evaluate the Safety of Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2600g
Drugs (7)
- Efalizumab Integrin alpha-L/beta-2 (LFA-1) inhibitor
- Erlizumab Integrin beta-2 negative modulator
- Lifitegrast Integrin alpha-L/beta-2 (LFA-1) antagonist
- Lifitegrast sodium Integrin alpha-L/beta-2 (LFA-1) antagonist
- MLN-01 Integrin beta-2 inhibitor
- MLNM-2201 Integrin beta-2 inhibitor
- Rovelizumab Integrin alpha-L/beta-2 (LFA-1) antagonist